Please ensure Javascript is enabled for purposes of website accessibility

Vir Biotechnology and GSK Launch Phase 2/3 Study of COVID-19 Antibody

By Jim Crumly – Aug 31, 2020 at 3:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The treatment to prevent hospitalization from COVID-19 could be available in the first half of 2021.

Vir Biotechnology (VIR 3.68%) and GlaxoSmithKline plc (GSK 3.18%) announced that they have started dosing patients in a phase 2/3 clinical trial of VIR-7831 (or GSK4182136, as it's also known), a monoclonal antibody for early treatment of COVID-19 patients to prevent the disease from worsening.

The study, named COMET-ICE, will enroll 1,300 patients worldwide with mild or moderate COVID-19 who are at high risk of progression to severe symptoms. The non-hospitalized patients in the double-blind trial will receive either a placebo or a single intravenous infusion of VIR-7831. The primary endpoint of the study will be the number of patients who worsen as defined by death or the need for hospitalization within 29 days. The companies expect early results before the end of the year, complete results in the first quarter of 2021, and early availability of the treatment in the first half of next year.

Antibodies surrounding a coronavirus.

Image source: Getty Images.

VIR-7831, a product of the collaboration between the British drug giant and the San Francisco-based biotech, is a monoclonal antibody that's been designed to mimic antibodies that have been isolated from COVID-19 survivors and enhanced for longer life, and that can enhance bioavailability in the lungs. The companies expect the to neutralize the SARS-CoV-2 virus, preventing it from infecting new cells while also stimulating the immune system to eliminate infected cells.

Vir and GSK also plan to start a phase 2 trial later this year of a second antibody candidate, VIR-7832, that has similar characteristics to VIR-7831 but could also have preventative effects that would allow it to be used as a vaccine.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GSK Stock Quote
GSK
GSK
$30.36 (3.18%) $0.94
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$19.99 (3.68%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.